


# pTurboRFP-PRL vector

The vector sequence has been compiled using the information from sequence databases, published literature, and other sources, together with partial sequences obtained by Evrogen. This vector has not been completely sequenced.



For vector sequence, please visit our Web site at http://www.evrogen.com/support/vector-info.shtml

#### Multiple cloning site (MCS)

 Afe I
 Xho I
 Hind III
 Hind III
 Pst I
 And I
 Band I

### **Location of features**

MCS: 12-96

TurboRFP

Kozak consensus translation initiation site: 90-100 Start codon (ATG): 97-99; Stop codon: 790-792 SV40 early mRNA polyadenylation signal

Polyadenylation signals: 946-951 & 975-980 mRNA 3' ends: 984 & 996

f1 single-strand DNA origin: 1043-1498

Eukaryotic promoter for expression of Kan<sup>r</sup> gene

-35 region: 1560-1565; -10 region: 1583-1588 Transcription start point: 1595

SV40 origin of replication: 1839-1974

SV40 early promoter Enhancer (72-bp tandem repeats): 1672-1743 & 1744-

1815 21-bp repeats: 1819-1839, 1840-1860 & 1862-1882

Early promoter element: 1895-1901 Major transcription start points: 1891, 1929, 1935 &

1940

Kanamycin/neomycin resistance gene

Neomycin phosphotransferase coding sequences: Start codon (ATG): 2023-2025; Stop codon: 2815-2817 G->A mutation to remove Pst I site: 2205

C->A (Arg to Ser) mutation to remove BssH II site: 2551 Herpes simplex virus (HSV) thymidine kinase (TK) polyadenylation signal

Polyadenylation signals: 3053-3058 & 3066-3071 pUC plasmid replication origin: 3402-4045

## References

Gorman (1985). "High efficiency gene transfer into mammalian cells." In: DNA cloning: A Practical Approach, Vol. II. Ed. by Glover. (IRL Press, Oxford, U.K.) Pp. 143–190.

Haas et al. (1996) "Codon usage limitation in the expression of HIV-1 envelope glycoprotein." Curr Biol, 6 (3): 315–324 / pmid: 8805248

Kozak (1987) "An analysis of 5'-noncoding sequences from 699 vertebrate messenger RNAs." Nucleic Acids Res, 15 (20): 8125–8148 / pmid: 3313277

## Vector description

Th

pTurboRFP-PRL is a promoterless vector encoding red (orange) fluorescent protein, TurboRFP, which can be used as *in vivo* reporter of gene expression. TurboRFP codon usage is optimized for high expression in mammalian cells (humanized) [Haas et al. 1996]. To increase mRNA translation efficiency, Kozak consensus translation initiation site is generated upstream of TurboRFP coding sequence [Kozak 1987].

Multiple cloning site (MCS) is located upstream of the Kozak consensus translation initiation site and can be used to clone a promoter or a promoter/enchancer combination of interest. Without the addition of a functional promoter, this vector will not express TurboRFP.

The vector backbone contains SV40 origin for replication in mammalian cells expressing SV40 T-antigen, pUC origin of replication for propagation in *E. coli* and f1 origin for single-stranded DNA production. SV40 polyadenylation signals (SV40 poly A) direct proper processing of the 3'-end of the reporter mRNA.

SV40 early promoter (P<sub>SV40</sub>) provides neomycin resistance gene (Neo<sup>r</sup>) expression to select stably transfected eukaryotic cells using G418. Bacterial promoter (P) provides kanamycin resistance gene expression (Kan<sup>r</sup>) in *E. coli*. Kan<sup>r</sup>/Neo<sup>r</sup> gene is linked with herpes simplex virus (HSV) thymidine kinase (TK) polyadenylation signals.

Note: The plasmid DNA was isolated from dam<sup>+</sup>-methylated *E.coli*. Therefore some restriction sites are blocked by methylation. If you wish to digest the vector using such sites you will need to transform the vector into a dam<sup>+</sup> host and make fresh DNA.

#### Expression in mammalian cells

The vector will express TurboRFP under the control of functional promoter cloned into the vector's MCS. pTurboRFP-PRL vector can be transfected into mammalian cells by any known transfection method. If required, stable transformants can be selected using G418 [Gorman 1985].

## Propagation in E. coli

Suitable host strains for propagation in *E. coli* include DH5alpha, HB101, XL1-Blue, and other general purpose strains. Plasmid incompatibility group is pMB1/ColE1. The vector confers resistance to kanamycin ( $30 \mu g/ml$ ) to *E. coli* hosts. Copy number in *E. coli* is about 500.

#### Notice to Purchaser:

Evrogen Fluorescent Protein Products (the Products) are intended for research use only. The Products are covered by U.S. Pat. 7,417,131 and other Evrogen Patents and/or Patent applications pending. By use of these Products, you accept the terms and conditions of the applicable Limited Use Label License.

MATERIAL SAFETY DATA SHEET INFORMATION: To the best of our knowledge, these products do not require a Material Safety Data Sheet. However, all the properties of these products (and, if applicable, each of their components) have not been thoroughly investigated. Therefore, we recommend that you use gloves and eye protection, and wear a laboratory coat when working with these products.

| Product   | Cat.#                                     | Size  |  |
|---|---|---|--|
| pTurboRFP-PRL vector                                  | FP235                                     | 20 $\mu$ g  |  |
| The price does not include delivery. The price varies | in different countries. Please contact yo | our local distributor for exact prices and delivery information |  |
| Vector type   | promoterless expression vector            |   |  |
| Reporter  | TurboRFP                                  |   |  |
| Reporter codon usage                                  | mammalian                                 |   |  |
| Promoter for TurboRFP                                 | NO  |   |  |
| Host cells  | mammalian, prokaryotic                    |   |  |
| Selection   | prokaryotic - kanamycin                   |   |  |
|   | eukaryotic - neom                         | nycin (G418)  |  |
| Replication   | prokaryotic - pUC                         | prokaryotic - pUC ori   |  |
|   | eukaryotic - SV40                         | ori   |  |
| Use   | Monitoring of acti                        | Monitoring of activity of different promoters and               |  |

promoter/enhancer combinations